• darkblurbg

    Towards a cure for type 1 diabetes

    Antigen based therapies
    Medical Technology
    Stem Cells

Diamyd Medical genomför företrädesemission

  • Diabetes

    More than 400 million people worldwide suffer from diabetes. 10-20% have an autoimmune form of the disease where the immune system attacks and destroys the insulin-producing beta cells. Autoimmune diabetes is a chronic disease and there is currently no cure.

  • Product Development

    Diamyd Medical develops the diabetes vaccine Diamyd®, based on the exclusively licensed GAD molecule. The Company’s licensed technologies GABA and Gliadin also have the potential to become key pieces of the puzzle to prevent, treat or cure autoimmune diabetes.

  • Clinical Trials

    The development of Diamyd Medical’s licensed technologies for GAD, GABA and Gliadin, in combination or with other substances with various mechanisms of action, is carried out in clinical trials and preclinical studies. Six clinical trials are currently ongoing.

THE COMPANY

Diamyd Medical is a Swedish diabetes company active in the field of pharmaceutical development
The share is listed on Nasdaq Stockholm First North (ticker: DMYD B)


Read More
 

We take great pleasure in reporting that Diamyd Medical continues to strengthen its position as a world leader in the development of Antigen Based Therapy for type 1 diabetes.

thumb Anders Essen-Möller
President and CEO
 
  Quarterly Report 1, January 2016

Dear Shareholders

We take great pleasure in reporting that Diamyd Medical continues to strengthen its position as a world leader in the development of Antigen Based Therapy for type 1 diabetes. A positive trend for the Diamyd® therapy could be reported from the end of the first 15-month period of the ongoing 30-month DIABGAD study. Limited six-month findings from the EDCR study will soon be available, as well as limited six-month findings from the DIAGNODE study.

Particularly pleasing is the growing interest shown by the pharmaceutical industry in our approach to combining GABA with antigen-based therapy for autoimmune diseases, not limited to type 1 diabetes, and for certain inflammatory disorders.